Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Category: Health

Shares of Hims & Hers Health dropped over 23% after the FDA announced the resolution of a shortage of semaglutide, impacting the company's compounded weight-loss drug offerings. CEO Andrew Dudum stated the company will monitor future shortages while continuing to provide personalized treatments legally.

Keywords: Hims & Hers Health, FDA, semaglutide

Source: Investopedia

Update At: 2/22/2025

Related Sources